Injectable vs topical peptides for skin: what actually works?

TL;DR

• Route usually matters more than the peptide name - most peptides are too large or too charged to cross the skin barrier in meaningful amounts.
• The rough dermatology threshold is about 500 daltons - above that, molecules don't penetrate intact skin well, and many cosmetic peptides sit above it.
• GHK-Cu is the standout exception - a copper-bound tripeptide of roughly 340 Da, small enough to reach living skin and signal there.
• "Contains peptides" is a marketing claim, not a delivery guarantee - larger signal peptides act mostly at the surface, and depth is formulation-dependent.
• Topical is the sensible default for surface goals; injection bypasses the barrier but turns a cosmetic choice into an investigational, physician-directed one.

Educational content, not medical advice. No doses or protocols appear; injectable use is physician-directed. Injectable peptides for skin are largely investigational; systemic GHK-Cu is not FDA-approved.

---

Walk down any skincare aisle in 2026 and you'll see "peptides" on half the labels - the beauty industry has flooded into the category. But there's an inconvenient physics problem the marketing skips: most peptides are too large and too charged to cross the skin barrier in meaningful amounts. So the real question isn't "peptide or not" - it's route. Whether a peptide is delivered topically or by injection often decides whether it does anything at all. Here's the honest breakdown, with GHK-Cu as the worked example.

The barrier problem - why route matters

Your skin's outer layer (the stratum corneum) is a deliberate barrier, and it's very good at keeping things out. The rough rule dermatology uses: molecules above roughly 500 daltons don't penetrate intact skin well. Many cosmetic peptides are larger than that, or too water-loving to diffuse through the lipid barrier - so a lot of "peptide serum" actives sit on the surface rather than reaching the living skin below.

That single fact frames the whole comparison:

• Topical = easy, low-risk, cosmetic - but delivery-limited. It works if the peptide is small enough (or formulated to penetrate) and acts where it can reach.
• Injectable = bypasses the barrier entirely and delivers systemically - but that's a bigger intervention with real regulatory and safety implications, and it's investigational for skin.

GHK-Cu as the case study

GHK-Cu is the best example because it's genuinely small - a copper-bound tripeptide (~340 Da) - so unlike most cosmetic peptides, it actually can penetrate skin to some degree topically, and it has real signaling activity (shifting gene expression toward repair and supporting collagen). That's why it shows up in both worlds:

• Topical GHK-Cu has the most legitimate cosmetic case of the copper peptides - small enough to reach living skin, with evidence for skin remodeling and barrier support. This is the well-established, low-risk use.
• Injectable/systemic GHK-Cu is investigational - it bypasses the barrier for a body-wide effect, but that's a different risk and regulatory category, and the systemic evidence is far thinner than the topical.

We go deep on exactly this trade-off in GHK-Cu: topical vs injection; the point here is the general principle it illustrates - small, penetrating peptide = topical can work; most others = the route is the bottleneck.

What the beauty boom gets right and wrong

Right: peptides can be legitimate skin actives, GHK-Cu chief among them, and topical delivery is genuinely low-risk. Bringing evidence-based copper peptides mainstream is a real positive.

Wrong: the flood also brought a lot of serums built around peptides that won't meaningfully penetrate, sold on the word "peptide" rather than on whether that specific molecule reaches its target. Bigger signal peptides (the Matrixyl-type pentapeptides and similar) act mostly at the surface and upper layers; whether they do much at depth is formulation-dependent and often oversold. "Contains peptides" is a marketing claim, not a delivery guarantee.

Choosing based on goal and risk

A rough, honest orientation (not a protocol):

• Surface-level goals - barrier support, fine-line appearance, general skin quality - are a reasonable fit for topical peptides like GHK-Cu, at low risk. Start here; it's the sensible default.
• Deeper or systemic goals push people toward injectables - but that's an investigational, higher-risk, physician-territory decision, not a cosmetic one, and the evidence bar should be correspondingly higher.
• For most people, most of the time, the topical route is the right starting point - and pairing a penetrating peptide with the foundational skin actives that are actually proven beats chasing an injectable for a surface goal. For an inflammation-plus-repair skin approach, the KPV + GHK-Cu protocol covers the pairing logic.

The bottom line

The peptide-serum boom is half real, half hype, and bioavailability is the line between them. Route usually matters more than the peptide name: most peptides don't cross skin well, so topical works best when the molecule is small and penetrating (GHK-Cu is the standout), while injectable delivery bypasses the barrier but turns a cosmetic choice into an investigational, supervised one. Match the route to the goal - and don't buy a serum on the word "peptide" alone.

Want the evidence-based version of peptide skincare? Vivre Labs approaches GHK-Cu and skin peptides by route and goal - topical where it's proven and low-risk, clearly labelled as investigational where it isn't - with honest delivery science, not label hype. Book a consult or explore the skin protocols. vivrelabs.com - Telegram · see the V-06 Radiance skin protocol.

Frequently asked questions

Do peptide creams actually work? Some do - if the peptide is small enough to penetrate (GHK-Cu is the best example) and acts where it can reach. Many cosmetic peptides are too large to cross the skin barrier meaningfully, so "contains peptides" isn't a guarantee of effect.

Are injectable peptides better than topical for skin? Injectables bypass the skin barrier and deliver systemically, but that's a bigger, investigational, physician-territory intervention with more risk and regulatory weight. For surface-level skin goals, topical is usually the sensible, lower-risk starting point.

Why does GHK-Cu work topically when other peptides don't? It's a small copper-bound tripeptide (~340 Da), below the rough penetration threshold, so it can actually reach living skin and signal there - unlike many larger cosmetic peptides.

Is injectable GHK-Cu safe or legal? Systemic GHK-Cu is investigational and not FDA-approved; topical cosmetic use is well established and low-risk. The injectable route should be physician-directed.

Related reading

• GHK-Cu: topical vs injection · GHK-Cu, skin and cellular repair · Do collagen supplements work? · Skin peptides: KPV + GHK-Cu
• Part of The Evidence-Based Guide to Looksmaxxing

---

Educational content, not medical advice. Topical cosmetic peptide use is low-risk; injectable/systemic peptide use for skin is investigational and should be physician-directed. Systemic GHK-Cu is not FDA-approved. SEA-market claims are subject to MAB requirements.

References

• Skin-penetration ~500 Da rule (Bos & Meinardi "500 Dalton rule"). · GHK-Cu: ~340 Da copper tripeptide; topical skin-remodeling and gene-expression evidence (Pickart & Margolina, 2015). · Cosmetic signal-peptide surface activity and formulation-dependent penetration. · Systemic GHK-Cu investigational status.